Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
| ▸ | AHCY | P23526 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7911779 | 0.81 | DYRK1A (0.42) | DYRK1ASCN2ACYP3A4PLAUNOS3 | |
| SCHEMBL7361765 | 0.79 | DYRK1A (0.41) | DYRK1ASCN2AALDH1A1CYP3A4PLAU | |
| SCHEMBL7841635 | 0.79 | HTT (0.34) | DYRK1AALDH1A1CYP3A4PLAUHTT | |
| SCHEMBL18708648 | 0.75 | HTT (0.43) | DYRK1AHTTKMT2A | |
| SCHEMBL15662633 | 0.75 | DYRK1A (0.38) | DYRK1ASCN2A | |
| SCHEMBL3675394 | 0.75 | PLAU (0.41) | DYRK1AALDH1A1PLAUNOS3NOS2 | |
| SCHEMBL31569579 | 0.75 | HTT (0.43) | DYRK1AHTTKMT2A | |
| SCHEMBL11708509 | 0.75 | HPGD (0.40) | DYRK1ASCN2APLAUAHCY | |
| SCHEMBL18925806 | 0.75 | NOS3 (0.43) | DYRK1AALDH1A1NOS3NOS2NOS1 | |
| Hydrochloric Acid SCHEMBL3156294 | 0.73 | PLAU (0.40) | DYRK1AALDH1A1PLAUNOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217213-A2 | COMPOSITIONS AND METHODS FOR TREATING RETINITIS PIGMENTOSA | OCTANT, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| CN-107567445-B | 2-phenyl-3H-imidazo [4,5-B ] pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ROR1 activity | 坎塞拉有限公司 | 2021-06-29 | — | — | CN | disclosed |
| EP-3253754-B1 | 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | KANCERA AB (SE) | 2021-03-31 | — | — | EP | disclosed |
| US-10550113-B2 | 2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | KANCERA AB (SE) | 2020-02-04 | — | — | US | disclosed |
| EP-3461825-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C Research Laboratories (KR) | 2019-04-03 | — | — | EP | disclosed |
| EP-2760865-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RES LAB (KR) | 2018-07-11 | — | — | EP | disclosed |
| CN-107567445-A | It can be used as 2 phenyl 3H imidazos [4,5 B] pyridine derivates of mammal EGFR-TK ROR1 activities inhibitor | 坎塞拉有限公司 | 2018-01-09 | — | — | CN | disclosed |
| US-20180002329-A1 | 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | KANCERA AB (SE) | 2018-01-04 | — | — | US | disclosed |
| CN-103889986-B | Novel heterocyclic derivatives and their use | C&C新药研究所 | 2017-07-21 | — | — | CN | disclosed |
| US-9586959-B2 | Substituted tricyclic heterocycles as histamine 4 receptor inhibitors | C&C RESEARCH LABORATORIES (KR) | 2017-03-07 | — | — | US | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1874768-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| CN-100358893-C | Certain novel imidazopyridines and uses thereof | ASTRAZENECA AB (SE) | 2008-01-02 | — | — | CN | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006113837-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
| CN-1684964-A | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2005-10-19 | — | — | CN | disclosed |
| EP-1539759-A1 | USE OF AND SOME NOVEL IMIDAZOPYRIDINES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004016611-A1 | USE OF AND SOME NOVEL IMIDAZOPYRIDINES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | DYRK1A 792/4885SCN2A 1611/4885ALDH1A1 1489/4885 |
| US-10550113-B2 | 2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | ROR1, RORB, RORA | DYRK1A 434/4885SCN2A 1672/4885ALDH1A1 317/4885 |
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | DYRK1A 980/4885SCN2A 4409/4885ALDH1A1 4166/4885 |
| US-20180002329-A1 | 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | ROR1, RORB, RORA | DYRK1A 434/4885SCN2A 1672/4885ALDH1A1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.